Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
We read with interest the recently published article by Davies et al. 1 In this study they found nilotinib to be an inhibitor, but not a substrate of ABCB1 and ABCG2. 1 We and others have previously demonstrated that dasatinib is a substrate of ABCB1 2, 3 and ABCG2. 2 Based on our and Davies et al.'s 1 findings, we speculate that a combination of nilotinib and dasatinib may be synergistic, as nilotinib-mediated inhibition of ABCB1 and ABCG2 may enhance the intracellular uptake and retention (IUR) of dasatinib. This would be analogous to the earlier described 4 synergy between nilotinib and imatinib, which we speculated to be due to an imatinib-mediated increase in nilotinib IUR. 5 Here we report the effect of nilotinib on 14 C-dasatinib IUR in parental and ABCB1-overexpressing cell lines. K562, CCRF-CEM cells, and their ABCB1-overexpressing respective sublines, K562-Dox and VBL-100, were incubated with 14 C-dasatinib with or without nilotinib for 2 h at 37 1C. The aqueous phase and cell pellet were then separated by centrifugation and the IUR of 14 C-dasatinib was assessed as described previously.
2 Nilotinib significantly increased 14 C-dasastinib IUR in the ABCB1-overexpressing K562-Dox (11.47±2.91 vs 34.52±9.78, P ¼ 0.007; Figure 1a ) and VBL-100 cells (9.4 ± 2.4 vs 18.24 ± 1.44, Po0.01; Figure 1c ), but not in their parental cells. To assess whether increased dasatinib IUR enhances dasatinib potency in an ABCB1-overexpressing cell line, K562-Dox cells were cultured with dasatinib, nilotinib, or a 1:4 ratio (based on IC50) combination of dasatinib and nilotinib for 2 h, and p-Crkl inhibition was assessed as described earlier. 2 The dose effect and synergy analysis was performed by using CalcuSyn Software (Biosoft, Cambridge, UK). In K562-Dox cells dasatinib and nilotinib IC50 were 98 and 400 nM, respectively. The combination indices (CIs) of the dasatinib and nilotinib mixture at effect dose (ED)50, ED75 and ED90 were 0.85, 0.74 and 0.65, respectively (Figures 2a and b ). These results demonstrate the synergistic effect of the dasatinib and nilotinib combination in K562-Dox cells. To assess the cell death mediated by this combination, K562-Dox cells were cultured with dasatinib, nilotinib or the combination (1:4 ratio), and cell death was assessed at 72 h. The combination of dasatinib and nilotinib induced significantly higher cell death than that induced by each individual drug alone, and the combination index at ED50 and ED75 were 0.41 and 0.65, respectively, confirming the synergistic effect of the dasatinib and nilotinib combination in K562-Dox cells (Table 1) . These results are consistent with the findings of Davies et al., 1 and suggest the potential for synergy between dasatinib and nilotinib in combination.
According to Davies et al., 1 nilotinib is also an ABCG2 inhibitor; however, in our study, nilotinib did not increase dasatinib IUR (19.74±2.86 vs 23.40±2.25; P ¼ 0.1) in K562-ABCG2 cell line (ABCG2-overexpressing cell line).
Davies et al. 1 also reported that, although nilotinib inhibited ABCB1-mediated efflux in an ABCB1-overexpressing cell line, they could not demonstrate a similar inhibitory effect in chronic myelogenous leukemia (CML)-CD34 þ cells. We compared the effect of nilotinib on 14 C-dasatinib IUR in CML-CD34 þ cells and mononuclear cells (MNCs). Unlike imatinib, 6 dasatinib IUR in CML-CD34 þ cells was not significantly lower than that in MNCs (8.22 ± 1.60 vs 8.08 ± 1.12, P ¼ 0.8; n ¼ 6). Moreover, nilotinib did not change 14 C-dasatinib IUR in MNCs (8.08±1.12 vs 8.05±1.0, P ¼ 0.9; n ¼ 6) and CML-CD34 þ (7.75 ± 1.69 vs 7.15 ± 2.06, P ¼ 0.8; n ¼ 4) cells. These findings may suggest that, although dasatinib is an ABCB1 substrate, ABCB1 may not be the major determinant of dasatinib IUR in CML-CD34 þ cells. This could be due to the lower ABCB1 expression and activity in CML-CP CD34 þ cells. 1, 7 In summary, our in vitro data support the finding of Davies et al.
1 that nilotinib is an ABCB1 inhibitor. Further, we demonstrate the potential benefit of combining dasatinib and nilotinib in CML cells overexpressing the ABCB1 efflux protein.
These in vitro studies suggest that the combination of low-dose dasatinib and nilotinib may provide an additive/synergistic antileukemic effect, which may be of particular relevance in leukemic stem cells that are considered to be both refractory to tyrosine kinase inhibitor (TKI) therapy and expressing ABCB1. 8 In the clinical setting, other possible advantages and concerns about combination therapy need to be considered. Thus, the findings presented here suggest that a combined TKI approach may be worthy of consideration in the setting of TKI resistance and stem cell refractoriness. The Wilms' tumor 1 (WT1) gene on chromosome 11p13 encodes a Krupple-like zinc finger transcription factor that may act as a tumor suppressor or oncogene in leukemogenesis. 1 Mutations in WT1 were initially identified in 10-15% of acute myeloid leukemia (AML) and 20% of biphenotypic leukemia. 2 Recently, the frequency of 10-15% WT1 mutations in adult AML with normal karyotypes was confirmed using relatively large cohorts of AML patients. [3] [4] [5] [6] In some studies WT1 mutations were implicated as an independent adverse prognostic marker for patients with normal karyotype AML (o60 years); [2] [3] [4] [5] however, in other WT1 mutations did not have impact on outcome. 6 Mutations in WT1 in AML often result in frame shifts introducing premature termination codons (PTC), [2] [3] [4] [5] but it is not known whether WT1 mutant transcripts are degraded by the nonsense-mediated RNA decay (NMD) surveillance system. 7 Here, we analyzed a cohort of 218 AML cases for WT1 mutations by RT-PCR for mutations in exons 6 to 9 (WT1-FOR3 5 0 -GAGAGCGATAACCACACAAC-3 0 (exon6) and WT1-REV4 5 0 -CTGTATGAGTCCTGGTGTGGG-3 0 (exon9) (bp1214-1619 (NM_024426)) followed by denaturing high performance liquid chromatography (dHPLC, sensitivity 10-20% (mutation dosage)) and sequencing. In six AML cases missense and in-frame insertion mutations were detectable in WT1 (no. 1-6, Table 1 ). These WT1 missense and in-frame mutants are expressed, because these transcripts were readily detectable by RT-PCR. Analyses of a diagnostic and relapse sample of AML case no. 2270 (no. 7, Table 1 ), carrying a double mutation, showed that the out-of-frame WT1 mutations were not present on a single allele and both present at relapse. Thus, the insertions of 11 bp and 1 bp do not result in the expression of a WT1 protein with an internal frame-shift, but encode truncated WT1 proteins from two alleles.
Following this RT-PCR strategy; we detected relatively small numbers of WT1 mutations (2.7%). [2] [3] [4] [5] In contrast, out of a diverse AML cohort of 351 AML samples, we were able to reliably detect 21 insertion/deletion mutations in exon 7 or 9 of WT1 (no. 8-26, Table 1 ) using genomic DNA PCR 3,5 followed by dHPLC (sensitivity 10-20% (mutation dosage)) and sequencing. The overall frequency of WT1 mutations in AML patients with a normal karyotype was 6.3 and 7.7% in AML patients with normal karyotypes younger than 60 years. WT1 mutations were present in patients carrying a favorable karyotype, that is, t(8;21) (n ¼ 1), inv(16) (n ¼ 2) and t(15;17) (n ¼ 2) (Table 1 ). This may suggest that mutations in WT1 cooperate with the fusion proteins AML1/ETO, CBFB/MYH11 and PML/RAR, respectively. WT1 mutations were more often present in AML with an FLT3 internal tandem duplication or NPM1 mutation (data not shown); however, none of these were statistically significant (Fisher's exact test). No association was found between WT1 mutations and other known acquired mutations in AML, that is, N-RAS-, K-RAS-or CEBPA mutations. By subcloning the WT1 PCR fragments of the five additional AML double mutants (Table 1) , we have shown that these were monoallelic. The overall WT1 mutation dosage was below 55%, thus, there is no direct indication that acquired uniparental disomy is involved in any of the AML cases. It is interesting to note that WT1
